Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
15.58
+0.11 (0.71%)
Apr 3, 2025, 2:45 PM CST
SHA:600535 Revenue
In the year 2024, Tasly Pharmaceutical Group had annual revenue of 8.50B CNY, down -2.03%. Tasly Pharmaceutical Group had revenue of 2.04B in the quarter ending December 31, 2024, a decrease of -3.19%.
Revenue
8.50B
Revenue Growth
-2.03%
P/S Ratio
2.72
Revenue / Employee
775.52K
Employees
10,958
Market Cap
23.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.50B | -175.87M | -2.03% |
Dec 31, 2023 | 8.67B | 36.58M | 0.42% |
Dec 31, 2022 | 8.64B | 685.47M | 8.62% |
Dec 31, 2021 | 7.95B | -5.62B | -41.43% |
Dec 31, 2020 | 13.58B | -5.42B | -28.54% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 27.98B |
Shenzhen Mindray Bio-Medical Electronics | 37.11B |
WuXi AppTec | 37.92B |
Aier Eye Hospital Group | 20.62B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
Shanghai United Imaging Healthcare | 10.30B |
Yunnan Baiyao Group Co.,Ltd | 40.03B |
Sichuan Biokin Pharmaceutical | 5.82B |